Study targets subretinal option for AMD treatment
December 24, 2019
This article was reviewed by Jeffrey S. Heier, MD
Learn how two large, phase III studies—HAWK and HARRIER—are the first that “individualize” treatment, says Pravin U. Dugel, MD.
Anti-VEGF
Anti-VEGF injections and glaucoma: Surgeons must watch IOP elevation
November 26, 2019
Anti-VEGF injections are associated with acute IOP spikes and chronic IOP rise in patients, and these increases in IOP need to be acknowledged and managed, according to Matthew Schlenker MD, MSc, FRCPC.
Meta-analysis on DME treatments updated to include treatment regimen
August 27, 2019
The choice of which anti-vascular endothelial growth factor (VEGF) agent to use on patients with diabetic macular edema (DME) may depend on a variety of variables, including b
Novel treatments in pipeline for diabetic eye disease
December 3, 2018
Patrik De Haes, MD, CEO of Oxurion NV, shares the latest updates in clinical studies at the [email protected] meeting in Chicago, Oct. 2018.
OCTA may be harbinger of anti-VEGF efficacy
September 26, 2018
When used one week after injection, optical coherence tomography angiography can help clinicians determine how effective their treatment has been on neovascular membrane reperfusion.
Anti-VEGFs can improve DRSS in majority of patients
September 14, 2018
Using a specific anti-vascular endothelial growth factor (VEGF) drug in patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR) can result i
Why you should consider laser therapy in young diabetic patients
May 23, 2018
Diabetic eye disease is occurring in younger populations, which means it's time to rethink anti-VEGF standards.
The time has come for gene therapy to treat retinal disease, AMD
March 26, 2018
With the first ocular gene therapy approved in the United States, Szilard Kiss, MD, points out that the gene therapy era for retinal disease has arrived, “and hopefully it will arrive for age-related macular degeneration.”
